Vertex Pharmaceuticals Founder Joshua Boger Has Sold $184 Million in VRTX Stock Across 1,769 Transactions
Joshua Boger, founder and former CEO of Vertex Pharmaceuticals, has filed 1,769 insider transactions totaling $184 million in sales, spanning the company's transformation from biotech startup to cystic fibrosis franchise leader.
Joshua Boger, founder and former CEO of Vertex Pharmaceuticals (VRTX), has sold $184 million in company stock across 1,769 insider transactions. Boger founded Vertex in 1989 and led the company through its early decades before stepping down as CEO in 2009, but he has continued filing as an insider through his remaining stake. His selling record spans the company's entire journey from biotech startup to the dominant franchise in cystic fibrosis treatment.
The Numbers
| Metric | Value |
|---|---|
| Career Sell Value | $184 million |
| Total Transactions | 1,769 |
| Last Transaction | Jun 23, 2025 |
| Career Buy Value | $0 |
What It Means
Boger's $184 million in career sales reflects decades of founder monetization at a company that has dramatically increased in value since his tenure. Vertex now commands a market cap above $100 billion, driven by its cystic fibrosis franchise (Trikafta/Kaftrio) and pipeline in pain, kidney disease, and gene editing. Boger's selling was most active during the earlier years when VRTX traded between $10-100; the stock's surge past $400 has made the remaining shares in his filing record exponentially more valuable.
With zero career purchases and a gradual selling pattern spanning nearly two decades, Boger fits the classic founder-diversifier profile. His 1,769 transactions — an unusually high count — reflect the granular execution of a long-running 10b5-1 plan that sold small lots at frequent intervals. His last filing in June 2025 suggests he still has a reportable position, though it has been substantially reduced from its peak.
What to Watch
- Whether Boger's filing activity continues to slow, potentially signaling an approaching end to his insider filing obligations as his remaining stake decreases
- Vertex's pipeline catalysts in pain (VX-548) and gene editing, which could drive the next leg of the stock's appreciation
- Broader insider sentiment at Vertex — if multiple insiders are selling simultaneously, it carries more weight than a single founder's systematic program
Related Research
Explore all researchNTLA has 311 tracked holders and 16 active top-20 names, giving investors a baseline for ownership follow-up.
ROKU has 724 institutional holders and 16 active top-20 names in the current ownership map.
Wellcome Trust reported $8.09B in 2026Q1 13F value across 21 holdings, led by V, AAPL, AMZN and MSFT.
RMAX has 130 tracked holders and 15 active top-20 names, giving investors a baseline for ownership follow-up.
OGN has 652 tracked holders and 15 active top-20 names, giving investors a baseline for ownership follow-up.